Market Cap 7.15B
Revenue (ttm) 3.03B
Net Income (ttm) -1.43B
EPS (ttm) N/A
PE Ratio 4.79
Forward PE 6.31
Profit Margin -47.23%
Debt to Equity Ratio 0.65
Volume 1,438,218
Avg Vol 2,489,010
Day's Range N/A - N/A
Shares Out 174.27M
Stochastic %K 11%
Beta 1.33
Analysts Sell
Price Target $57.43

Company Profile

Alexandria Real Estate Equities, Inc. an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Mega campus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland,...

Industry: REIT - Office
Sector: Real Estate
Phone: 626 578 0777
Fax: 626 578 0896
Website: www.are.com
Address:
26 North Euclid Avenue, Pasadena, United States
StockFactz
StockFactz May. 1 at 7:43 PM
$ARE If it can fill this gap and also break above the upper trend line for a second time I think it can recover to $50 range sooner than expected. But I also would not count on big institutional buying above $44 before a catalyst, seems like they are content to wait or slowly accumulate at low $40 until a big buyer with conviction forces the price up, then there will be a feeding frenzy.
0 · Reply
StockFactz
StockFactz May. 1 at 7:35 PM
$ARE The main risk in the monte carlo distribution I modelled is either if dividend is cut further which seems extrodinarly unlikely considering there is plenty of free cash flow and cash on hand, even if occupancy drops another 4-5% there is a signficant buffer since they made a bigger inital cut. The only other risk is if fundamentals materially deterioate even more in the next year which also seems unlikely. Keep in mind that occupancy rates are also achored due to long standing leases and also dispositions. Occupancy quite literally cannot fall below 80% in the next couple years so the downside risk is about 7% further occupany drop which also seems extremely unlikely. The floor hasn't been found yet (or at least confirmed, as only time will tell) but it seems like 85% or so is a very likely bottom. This is considering that while Q1 had weak leasing data there is also a lot of evidence that biotech leasing will pick up broadly in H2 and 2027.
0 · Reply
StockFactz
StockFactz May. 1 at 7:28 PM
$ARE At $35 the P/B is 0.35X which is abbysmal and unheard of for a company that is not on the precipice of collapse. At $60 the P/B is still only 0.67X which is still quite low for a company of this stature and repuatation. Same with P/FFO, which is hovering around 6X. Keep in mind average REIT is 14X, and AREs P/FFO is already signfincantly buoyed by the fact that FFO is currently down on the year. AREs historical average was closer to 20X which was also driven by higher growth expectations.
0 · Reply
StockFactz
StockFactz May. 1 at 7:21 PM
$ARE I ran a monte carlo probability distribution and it's essentially 8:1 odds that this will go to ~$65 vs ~$35 the question is just when in the next couple months or even year. This is the kind of thing that any hedge fund in this space would flag immediately. Price is essentially anchored around $35 meaning it very likely won't go lower since it's the level that is fundamentally supported by dividend yield floor, and even the P/FFO ratio which fundamentally can't justify any lower multiple, as well as P/B floor. On the upside the ceiling that is pulling the price up is around $90 based on NAV, previous conservative P/FFO ratios and P/B ratios. Hedge funds that are buying in at this point are in a good position, they've been accumulating at 39-44 level for weeks now. Might trade in this range for a while I'm sure they're in no rush to shoot this back up when they can quietly just buy at these levels at wait for the inevitable sentiment reversal whenever a catalyst comes.
0 · Reply
Doozio
Doozio May. 1 at 1:34 AM
$ARE if 30 doesn’t hold…. 🐑👀
0 · Reply
Doozio
Doozio May. 1 at 1:33 AM
$ARE YO stupit? If da 🧠 is on da outside yo bum 🐑 bettah hope 30 holds. If not next support is……
1 · Reply
Daniel3303
Daniel3303 Apr. 30 at 7:32 PM
$ARE have people notice the uptick in short interest along with the high short ratio (FINRA) in recent weeks?
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 30 at 5:35 PM
$ARE entire biotech market ripping up today, $XBI up 2%. Projected biotech IPOs in 2026 projected to be ~3-4x of 2025. Yet the most trusted biotech landlord is down due to soft leasing in Q1 which everyone already knew was going to happen. It’s almost as if commercial real estate is a lagging indicator 🤯. These analysts are morons
0 · Reply
StockFactz
StockFactz Apr. 30 at 5:10 PM
$ARE You could be selling a $10 Bill for $5 and some people would call it a value trap because there might be a possibility that someone tears up the $10 Bill and then sets it on fire
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Apr. 30 at 5:01 PM
$ARE took some today under 41 any chance joel shows some support with a buy ?
1 · Reply
Latest News on ARE
5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 5 weeks ago

5 ‘Healthy' Dividends Paying Up To 14.1%

BME DOC HQH PFE


Private Credit Default Rates Could Hit 15%, UBS Warns

Feb 25, 2026, 10:59 AM EST - 2 months ago

Private Credit Default Rates Could Hit 15%, UBS Warns

ARES BX OWL


Alexandria Real Estate Equities Transcript: Investor Day 2025

Dec 3, 2025, 8:00 AM EST - 5 months ago

Alexandria Real Estate Equities Transcript: Investor Day 2025


Alexandria Real Estate Equities Earnings Call Transcript: Q2 2025

Jul 22, 2025, 2:00 PM EDT - 10 months ago

Alexandria Real Estate Equities Earnings Call Transcript: Q2 2025


Alexandria Real Estate Equities Transcript: Investor Day 2023

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alexandria Real Estate Equities Transcript: Investor Day 2023


StockFactz
StockFactz May. 1 at 7:43 PM
$ARE If it can fill this gap and also break above the upper trend line for a second time I think it can recover to $50 range sooner than expected. But I also would not count on big institutional buying above $44 before a catalyst, seems like they are content to wait or slowly accumulate at low $40 until a big buyer with conviction forces the price up, then there will be a feeding frenzy.
0 · Reply
StockFactz
StockFactz May. 1 at 7:35 PM
$ARE The main risk in the monte carlo distribution I modelled is either if dividend is cut further which seems extrodinarly unlikely considering there is plenty of free cash flow and cash on hand, even if occupancy drops another 4-5% there is a signficant buffer since they made a bigger inital cut. The only other risk is if fundamentals materially deterioate even more in the next year which also seems unlikely. Keep in mind that occupancy rates are also achored due to long standing leases and also dispositions. Occupancy quite literally cannot fall below 80% in the next couple years so the downside risk is about 7% further occupany drop which also seems extremely unlikely. The floor hasn't been found yet (or at least confirmed, as only time will tell) but it seems like 85% or so is a very likely bottom. This is considering that while Q1 had weak leasing data there is also a lot of evidence that biotech leasing will pick up broadly in H2 and 2027.
0 · Reply
StockFactz
StockFactz May. 1 at 7:28 PM
$ARE At $35 the P/B is 0.35X which is abbysmal and unheard of for a company that is not on the precipice of collapse. At $60 the P/B is still only 0.67X which is still quite low for a company of this stature and repuatation. Same with P/FFO, which is hovering around 6X. Keep in mind average REIT is 14X, and AREs P/FFO is already signfincantly buoyed by the fact that FFO is currently down on the year. AREs historical average was closer to 20X which was also driven by higher growth expectations.
0 · Reply
StockFactz
StockFactz May. 1 at 7:21 PM
$ARE I ran a monte carlo probability distribution and it's essentially 8:1 odds that this will go to ~$65 vs ~$35 the question is just when in the next couple months or even year. This is the kind of thing that any hedge fund in this space would flag immediately. Price is essentially anchored around $35 meaning it very likely won't go lower since it's the level that is fundamentally supported by dividend yield floor, and even the P/FFO ratio which fundamentally can't justify any lower multiple, as well as P/B floor. On the upside the ceiling that is pulling the price up is around $90 based on NAV, previous conservative P/FFO ratios and P/B ratios. Hedge funds that are buying in at this point are in a good position, they've been accumulating at 39-44 level for weeks now. Might trade in this range for a while I'm sure they're in no rush to shoot this back up when they can quietly just buy at these levels at wait for the inevitable sentiment reversal whenever a catalyst comes.
0 · Reply
Doozio
Doozio May. 1 at 1:34 AM
$ARE if 30 doesn’t hold…. 🐑👀
0 · Reply
Doozio
Doozio May. 1 at 1:33 AM
$ARE YO stupit? If da 🧠 is on da outside yo bum 🐑 bettah hope 30 holds. If not next support is……
1 · Reply
Daniel3303
Daniel3303 Apr. 30 at 7:32 PM
$ARE have people notice the uptick in short interest along with the high short ratio (FINRA) in recent weeks?
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 30 at 5:35 PM
$ARE entire biotech market ripping up today, $XBI up 2%. Projected biotech IPOs in 2026 projected to be ~3-4x of 2025. Yet the most trusted biotech landlord is down due to soft leasing in Q1 which everyone already knew was going to happen. It’s almost as if commercial real estate is a lagging indicator 🤯. These analysts are morons
0 · Reply
StockFactz
StockFactz Apr. 30 at 5:10 PM
$ARE You could be selling a $10 Bill for $5 and some people would call it a value trap because there might be a possibility that someone tears up the $10 Bill and then sets it on fire
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Apr. 30 at 5:01 PM
$ARE took some today under 41 any chance joel shows some support with a buy ?
1 · Reply
Joby099
Joby099 Apr. 30 at 10:38 AM
0 · Reply
Daniel3303
Daniel3303 Apr. 30 at 1:03 AM
$ARE the only reason I can think of to short this is removal from SP500, but it is impossible to be sure it will happen and the bull case is stronger
0 · Reply
Joby099
Joby099 Apr. 29 at 9:46 PM
0 · Reply
lextrading
lextrading Apr. 29 at 6:28 PM
$ARE Someone blocked me for my previous chart. Here we are - at the 40 uptrend. This needs to hold or we'll see ~35. I don't make the rules.
2 · Reply
StockFactz
StockFactz Apr. 29 at 6:22 PM
$ARE Assuming $2.9 billion disposition of non core assets goes through as intended, this would reinforce a basic floor valuation of $92 per share by EoY. On top of the $92 will grant the remaining real estate asset valuation a modest +15% premium for the mega campus boost ($15 Billion * 1.15 = $17.25 billion) + $7 Billion cash. Total market cap floor would be $24.25 Billion or ~$123 per share. Then let's deduct a generous -20% as a penalty for potential capex losses, and add in an additional -15% penalty for short term negative rent price growth that they will have to extend in the next couple quarters before real estate catches up to the leading indicators of the biotech recovery that is materializing. 123 - 123 * 0.35 = $79.50
0 · Reply
StockFactz
StockFactz Apr. 29 at 6:10 PM
$ARE I also want to make one more point with my math here. The dispositions they are selling would place them at with a theoretical market cap floor of $18 billion or around $92 per share. However these $2.9 billion dispositions are actually considered the least valuable in their portfolio since their megacampuses have significantly higher tenancy and occupancy than standalone (~15-30% multiplier). So if we carry that math and assume a 15-30% premium on their remaining real estate it would be even greater likely closer to $105. If we want to give them a capex penalty of potentially having to weather some lower occupancy for a while an argument can certainly be made of like a -20% penalty on valuation, but right now the penalty is closer to -60%. Someone correct me if I'm wrong this just doesn't seem to make sense.
0 · Reply
StockFactz
StockFactz Apr. 29 at 6:02 PM
$ARE Starting to believe more that funds are just using this as a vessel to short scalp and then turn around and pump but that certainly can't last forever with the fundamentals. Cash value is so divorced from the current market valuation and that's even factoring in the extreme bearsish multiplier the market is assigning (imo unjustly) to the stock. If we assign a 9% cap rate to their real estate assets (placing them in the same category as the worst performing traditional office REITs) their real estate would be roughly valued at $20.5 billion. Subtracting liabilities and adding cash position would give them a market cap of around $10 billion or 20% higher than it is right now, roughly ~$51.
1 · Reply
StockFactz
StockFactz Apr. 29 at 5:45 PM
$ARE Dispositions usually take 6-12 months to complete right? In the call I recall them saying about 80% of the dispositions were already in an agreement/LOI phase which while not binding is a pretty decent indicator that $2.9 billion worth of dispositions will occur as promised or at least be close to that. $2.9 billion in disposition for ~10% of the assets would firmly reinforce the stated NAV. Total real estate assets would be around $29 billion, total liabilities around $15 billion. 29 - 15 = $14 billion. Add on top of that their $4 billion cash position would give their asset valuation around $18 billion. Legit 2.5X of the current market cap. Am I missing something or is this kind of crazy?
0 · Reply
anachartanalyst
anachartanalyst Apr. 29 at 3:02 PM
$ARE https://anachart.com/wp-content/uploads/2026/04/1777474918_soc-img.jpg
0 · Reply
weko
weko Apr. 29 at 11:11 AM
$ARE Hit its weekly trend line yesterday and also a 17 year low. Chart wise it looks like the time to buy. Dividend at 10%
1 · Reply
Joby099
Joby099 Apr. 29 at 10:02 AM
0 · Reply
FDAvalid
FDAvalid Apr. 29 at 3:20 AM
$ARE $CAC $CNC $ERAS $KIDZ The Erasca bloodbath is here, and it is a total DECEPTION. While the retail bag holders were busy dreaming of "best-in-class" results, the low-energy hedge funds were already laughing. They entered at $2, pumped the hype, and used you as EXIT LIQUIDITY while the stock cratered over 40% today. 📉🤡 The truth is finally out: Erasca borrowed FAKE CHINESE DATA (41% ORR) to cover up a pathetic 14% American failure rate. 🇨🇳🚮 Even worse, they tried to hide a GRADE 5 DEATH in a sneaky 8-K filing, claiming the Chinese safety profile wasn't applicable. The market isn't buying the lie! One TREATMENT-RELATED DEATH from lung failure is the end of the line. 🪦💨
0 · Reply